A Study to Determine the Capacity of VAK694 When Combined With Allergen Immunotherapy to Bring About Specific Immune Tolerance

NCT01018693 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Seasonal Allergic Rhinitis

Interventions

DRUG: VAK694; Alutard Avanz SQ
DRUG: VAK694 placebo infusion; Alutard Avanz SQ
DRUG: VAK694 placebo infusion; Saline

Sponsor

Novartis Pharmaceuticals